Phase 2 N=131 Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain
Cannabis · Low Back Pain · Neuropathic Pain
Primary: Numerical Pain Intensity — 6.03; 6.11; 6.24; 5.97 score on a scale — p=0.78
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=674 Improving COVID-19 Vaccine Uptake Among Black and Latino Youth
COVID-19
Primary: COVID-19 Vaccination Rate for Eligible Children — 21.3; 33.5; 16.4; 26.7 Percent of participants vaccinated
Phase 2 N=200 Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain
Soft Tissue Injuries · Contusions · Strains
Primary: Change of Pain-on-movement (POM) Compared to Baseline — -50.7; -21.6 units on a scale — p=< 0.0001
N/A N=85 The FAITH! Trial: A mHealth Intervention to Improve Cardiovascular Health Among African-Americans
Cardiovascular Diseases · Physical Activity · Diet Modification
Primary: Life's Simple 7 Composite Score Change — 1.88; 0.74 units on a scale — p=<0.0001
Phase 3 N=588 The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
MDR-TB
Primary: STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76) — 0; 133; 162; 122 Participants
N/A N=5,411 Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing
Opioid Use · Opioid-Related Disorders
Primary: Subacute Phase - More Than 7 Days of Opioids — 1.9; 12.2 % of participants — p=<.001
Phase 2 N=100 Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Change in ALSFRS-R Slope — 0.229; 0.224 ALSFRS-R points per week — p=0.984
N/A N=172 Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19
Diabetes Mellitus, Type 2 · Covid19
Primary: Hospital Readmission Rate Within 30 Days of Discharge — 24; 13 Participants — p=0.0626
N/A N=1,761 Group Antenatal Care and Delivery Project
Antenatal Care
Primary: Change in Ability to Identify Danger Signs in Pregnancy — 1.8; 1.7; 3.4; 2.2 units on a scale
N/A N=24 SMS System for Patients With Uncontrolled Hypertension
Hypertension
Primary: Number of Participants Screened — 12; 12 participants
Phase 2 N=668 A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
Coronavirus · Covid19 · SARS-CoV-2
Primary: Number of Participants Who Experienced a Solicited Adverse Event (AE) Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2 — 9; 5; 253…
Phase 3 N=1,459 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)
Covid19
Primary: Time to Sustained Recovery in Days — 11; 12 days
Phase 2 N=25 Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Lymphoma
Primary: Progression-free Survival at 1 Year — 33.3 proportion of progression-free pts
N/A N=77 Reducing Traffic Pollution Exposure Improves Blood Pressure
Air Pollution
Primary: Systolic Blood Pressure (SBP) — 122.3; 120.83; 119.9 mmHg
Phase 2 N=193 Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Malignant Neoplasm of Breast · Breast Cancer
Primary: Percentage of Participants With Two-Year Disease-Free Survival (DFS) — 56.6; 62.4 percentage of participants